The oversubscribed round will scale up manufacturing and research for the bioactive protein developer.
"We are at an exciting stage of development, with new funds facilitating our next phase of rapid growth as we continue our mission of providing more reliable tools for research and bio-manufacturing. Our platform provides an improved process for complex protein manufacture at exceptionally high purity and unique engineered products that address specific challenges for stem cell biology. Growth factors are essential reagents for all stem cell manufacturing, and therefore critical for the delivery of cell therapies and cultivated meats."
The cyber-security business secured the investment to support its sales strategy and reach new markets.
"This is a great addition to our funding round and we are very grateful for the help and guidance provided by Henley Business Angels. We are looking forward to updating the members with the progress made."
The clinical stage pharmaceutical company raised the capital from Mankind Pharma to advance its lead cancer cachexia asset.
"We are thrilled to announce the successful closing of this financing round, which brings our total seed funding to £10 million, well ahead of our original target. The financing includes support from both longstanding and new investors, notably Mankind Pharma, demonstrating confidence in our strategic goal to develop innovative globally approved treatments for cancer cachexia and other muscle wasting conditions. We are particularly pleased by the support from Mankind and warmly welcome Atish Majumdar to our Board of Directors. With these funds, we will complete feasibility activities for the clinical development programme for S-pindolol benzoate, which has shown promising potential efficacy in this area of major unmet need."
The investment from BT Group will accelerate the rollout of ARROW technology and scale automated drone operations across the UK.
"With BT Group, Altitude Angel has a partner which shares its ambition to make automated commercial drone operations at scale in the UK a day-to-day reality."
